{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"80"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"97"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"61"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}]}],"title":"Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"268"},{"groupId":"OG001","value":"247"}],"units":"Participants"}],"description":"Maximum grade experienced among all treated and eligible patients. The grades are described by severity. Grade 1 is the lowest (most mild) and Grade 5 being death (most severe). Adverse events were analyzed across cohorts since disease site was considered independent of AEs.","groups":[{"description":"Paclitaxel 175 mg/m2 IV over 3 hours Day 1 Carboplatin (AUC=6) IV Day 1 Repeat q 3 weeks x 6-10 cycles","id":"OG000","title":"Regimen I - Uterine and Non-Uterine Subjects"},{"description":"Ifosfamide 1.6 g/m2 IV days 1, 2, 3 Mesna Paclitaxel 135 mg/m2 by 3-hour infusion on Day 1 Repeat q 3 weeks x 6-10 cycles. G-CSF Support: Filgrastim or Pegfilgrastim beginning Day 4-6","id":"OG001","title":"Regimen II - All Uterine and Non-Uterine Subjects"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Treated and Eligible subjects. Adverse events were analyzed across cohorts since disease site was considered independent of AEs.","reportingStatus":"POSTED","timeFrame":"Patients were assessed for adverse events during active protocol treatment and up to 30 days after the last cycle of treatment on the protocol.","title":"Incidence of Adverse Events as Assessed by CTCAE Version 3.0","type":"SECONDARY","unitOfMeasure":"Participants"}